Literature DB >> 19351835

Defective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase.

Elizabeth Alli1, Vandana B Sharma, Preethi Sunderesakumar, James M Ford.   

Abstract

Subtypes of breast cancer that represent the two major types of epithelial cells in the breast (luminal and basal) carry distinct histopathologic profiles. Breast cancers of the basal-like subtype, which include the majority of hereditary breast cancers due to mutations in the breast cancer susceptibility gene 1 (BRCA1), frequently assume triple-negative status, i.e., they lack expression of estrogen receptor-alpha and progesterone receptor, and lack overexpression or amplification of the HER2/NEU oncogene. Defects in DNA damage response pathways result in genome instability and lead to carcinogenesis, but may also be exploited for therapeutic purposes. We analyzed repair of oxidative DNA damage by the base-excision repair (BER) pathway, which when aberrant leads to genomic instability and breast carcinogenesis, in cell lines that represent the different subtypes of breast cancer and in the presence of BRCA1 deficiency. We found that basal-like and BRCA1-mutated breast cancer cells were defective in BER of oxidative DNA damage, and that this defect conferred sensitivity to inhibition of poly(ADP-ribose) polymerase, a DNA repair enzyme. The defect may be attributed, at least in part, to a novel role for BRCA1 in the BER pathway. Overall, these data offer preventive, prognostic, and therapeutic usefulness.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19351835      PMCID: PMC2681413          DOI: 10.1158/0008-5472.CAN-08-4016

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  49 in total

1.  In vitro repair of oxidative DNA damage by human nucleotide excision repair system: possible explanation for neurodegeneration in xeroderma pigmentosum patients.

Authors:  J T Reardon; T Bessho; H C Kung; P H Bolton; A Sancar
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-19       Impact factor: 11.205

Review 2.  The role of the BRCA1 tumor suppressor in DNA double-strand break repair.

Authors:  Junran Zhang; Simon N Powell
Journal:  Mol Cancer Res       Date:  2005-10       Impact factor: 5.852

3.  The effect of p53-RNAi and p53 knockout on human 8-oxoguanine DNA glycosylase (hOgg1) activity.

Authors:  Aditi Chatterjee; Elizabeth Mambo; Motonobu Osada; Sunil Upadhyay; David Sidransky
Journal:  FASEB J       Date:  2005-11-17       Impact factor: 5.191

4.  Photodynamic treatment of adenoviral vectors with visible light: an easy and convenient method for viral inactivation.

Authors:  F H Schagen; A C Moor; S C Cheong; S J Cramer; H van Ormondt; A J van der Eb; T M Dubbelman; R C Hoeben
Journal:  Gene Ther       Date:  1999-05       Impact factor: 5.250

Review 5.  Reactive oxygen species in tumor progression.

Authors:  Peter Storz
Journal:  Front Biosci       Date:  2005-05-01

6.  Brca1-deficient murine mammary epithelial cells have increased sensitivity to CDDP and MMS.

Authors:  Magdalene K Sgagias; Kay-Uwe Wagner; Brad Hamik; Scott Stoeger; Rebecca Spieker; L Julie Huber; Lewis A Chodosh; Kenneth H Cowan
Journal:  Cell Cycle       Date:  2004-11-08       Impact factor: 4.534

7.  Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer.

Authors:  A F Gazdar; V Kurvari; A Virmani; L Gollahon; M Sakaguchi; M Westerfield; D Kodagoda; V Stasny; H T Cunningham; I I Wistuba; G Tomlinson; V Tonk; R Ashfaq; A M Leitch; J D Minna; J W Shay
Journal:  Int J Cancer       Date:  1998-12-09       Impact factor: 7.396

8.  Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype.

Authors:  Sunil R Lakhani; Jorge S Reis-Filho; Laura Fulford; Frederique Penault-Llorca; Marc van der Vijver; Suzanne Parry; Timothy Bishop; Javier Benitez; Carmen Rivas; Yves-Jean Bignon; Jenny Chang-Claude; Ute Hamann; Cees J Cornelisse; Peter Devilee; Matthias W Beckmann; Carolin Nestle-Krämling; Peter A Daly; Neva Haites; Jenny Varley; Fiona Lalloo; Gareth Evans; Christine Maugard; Hanne Meijers-Heijboer; Jan G M Klijn; Edith Olah; Barry A Gusterson; Silvana Pilotti; Paolo Radice; Siegfried Scherneck; Hagay Sobol; Jocelyne Jacquemier; Teresa Wagner; Julian Peto; Michael R Stratton; Lesley McGuffog; Douglas F Easton
Journal:  Clin Cancer Res       Date:  2005-07-15       Impact factor: 12.531

9.  Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.

Authors:  Helen E Bryant; Niklas Schultz; Huw D Thomas; Kayan M Parker; Dan Flower; Elena Lopez; Suzanne Kyle; Mark Meuth; Nicola J Curtin; Thomas Helleday
Journal:  Nature       Date:  2005-04-14       Impact factor: 69.504

10.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.

Authors:  Hannah Farmer; Nuala McCabe; Christopher J Lord; Andrew N J Tutt; Damian A Johnson; Tobias B Richardson; Manuela Santarosa; Krystyna J Dillon; Ian Hickson; Charlotte Knights; Niall M B Martin; Stephen P Jackson; Graeme C M Smith; Alan Ashworth
Journal:  Nature       Date:  2005-04-14       Impact factor: 69.504

View more
  74 in total

1.  The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy.

Authors:  M Javle; N J Curtin
Journal:  Ther Adv Med Oncol       Date:  2011-11       Impact factor: 8.168

2.  BRCA1 is required for postreplication repair after UV-induced DNA damage.

Authors:  Shailja Pathania; Jenna Nguyen; Sarah J Hill; Ralph Scully; Guillaume O Adelmant; Jarrod A Marto; Jean Feunteun; David M Livingston
Journal:  Mol Cell       Date:  2011-09-29       Impact factor: 17.970

3.  The relationship between five non-synonymous polymorphisms within three XRCC genes and gastric cancer risk in a Han Chinese population.

Authors:  Huansong Gong; He Li; Jing Zou; Jia Mi; Fang Liu; Dan Wang; Dong Yan; Bin Wang; Shuping Zhang; Geng Tian
Journal:  Tumour Biol       Date:  2015-11-21

4.  Correcting errors in the BRCA1 warning system.

Authors:  Yanping Liang; William J Dearnaley; Nick A Alden; Maria J Solares; Brian L Gilmore; Kevin J Pridham; A Cameron Varano; Zhi Sheng; Elizabeth Alli; Deborah F Kelly
Journal:  DNA Repair (Amst)       Date:  2018-11-22

Review 5.  Triple-negative breast cancer: disease entity or title of convenience?

Authors:  Lisa Carey; Eric Winer; Giuseppe Viale; David Cameron; Luca Gianni
Journal:  Nat Rev Clin Oncol       Date:  2010-09-28       Impact factor: 66.675

Review 6.  Where Do We Stand on the Integration of PARP Inhibitors for the Treatment of Breast Cancer?

Authors:  Narjust Duma; Kelly C Gast; Grace M Choong; Roberto A Leon-Ferre; Ciara C O'Sullivan
Journal:  Curr Oncol Rep       Date:  2018-06-08       Impact factor: 5.075

7.  Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105.

Authors:  Melinda L Telli; Kristin C Jensen; Shaveta Vinayak; Allison W Kurian; Jafi A Lipson; Patrick J Flaherty; Kirsten Timms; Victor Abkevich; Elizabeth A Schackmann; Irene L Wapnir; Robert W Carlson; Pei-Jen Chang; Joseph A Sparano; Bobbie Head; Lori J Goldstein; Barbara Haley; Shaker R Dakhil; Julia E Reid; Anne-Renee Hartman; Judith Manola; James M Ford
Journal:  J Clin Oncol       Date:  2015-04-06       Impact factor: 44.544

8.  TUSC4 functions as a tumor suppressor by regulating BRCA1 stability.

Authors:  Yang Peng; Hui Dai; Edward Wang; Curtis Chun-Jen Lin; Wei Mo; Guang Peng; Shiaw-Yih Lin
Journal:  Cancer Res       Date:  2014-12-05       Impact factor: 12.701

9.  Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.

Authors:  Melinda L Telli; Kirsten M Timms; Julia Reid; Bryan Hennessy; Gordon B Mills; Kristin C Jensen; Zoltan Szallasi; William T Barry; Eric P Winer; Nadine M Tung; Steven J Isakoff; Paula D Ryan; April Greene-Colozzi; Alexander Gutin; Zaina Sangale; Diana Iliev; Chris Neff; Victor Abkevich; Joshua T Jones; Jerry S Lanchbury; Anne-Renee Hartman; Judy E Garber; James M Ford; Daniel P Silver; Andrea L Richardson
Journal:  Clin Cancer Res       Date:  2016-03-08       Impact factor: 12.531

10.  BRCA1 pathway function in basal-like breast cancer cells.

Authors:  Sarah J Hill; Allison P Clark; Daniel P Silver; David M Livingston
Journal:  Mol Cell Biol       Date:  2014-08-04       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.